Related Experiment Videos
[Anti-PCNA antibody]
1Department of Medicine, Juntendo University, Tokyo.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|August 1, 1993
Summary
Antibodies to proliferating cell nuclear antigen (PCNA) are useful clinical markers for systemic lupus erythematosus (SLE). These anti-PCNA antibodies indicate higher risks of kidney and CNS involvement and thrombocytopenia in SLE patients.
Area of Science:
- Immunology
- Molecular Biology
- Cell Biology
Context:
- Proliferating cell nuclear antigen (PCNA) is a nuclear antigen predominantly expressed in proliferating cells.
- PCNA is a protein with a molecular weight of approximately 33 kD and an isoelectric point of 4.8.
- PCNA expression increases during the late G1 and S phases of the cell cycle, preceding DNA synthesis.
Purpose:
- To characterize the structure and function of PCNA.
- To investigate the utility of anti-PCNA antibodies as clinical markers for systemic lupus erythematosus (SLE).
- To explore the association of anti-PCNA antibodies with specific clinical manifestations and treatment responses in SLE patients.
Summary:
- Antibodies to PCNA were detected in a subset of SLE patients.
- Anti-PCNA antibodies were identified in 2-5% of SLE patients using double immunodiffusion (DID).
- These antibodies are associated with a higher frequency of renal and central nervous system (CNS) involvement and thrombocytopenia in SLE patients.
Impact:
- Anti-PCNA antibodies serve as a valuable clinical marker for SLE, despite their low frequency.
- Elevated anti-PCNA antibody titers can precede proteinuria development and decrease with corticosteroid treatment in SLE patients.
- Anti-PCNA antibodies are also useful tools for detecting activated lymphocytes and malignant proliferating cells.